

## Special Issue

# Colon-Targeted Drug Delivery using Prodrug Approach

### Message from the Guest Editor

Colon-targeted drug delivery (CTDD) implies transport of a drug to the large intestine with no significant loss in the upper gastrointestinal tract upon oral administration of the drug. This increases drug availability at the target site and decreases drug absorption into blood, thus improving therapeutic and toxicological properties. For this reason, CTDD is applied to drugs for the treatment of colonic diseases, such as inflammatory bowel disease (IBD) and constipation. A prodrug, an inactive derivative of a drug, is designed to circumvent pharmacokinetic issues and be subsequently activated to the drug through biochemical processes within the body. Adoption of prodrug concept to CTDD gives a birth to colon-targeted prodrug (CTP). To date, a number of hydrophilic or polymeric carrier-linked CTPs, activated by microbial enzymes in the large intestine, have been developed, largely aiming at IBD treatment. Any contributions to add knowledge and insights on CTP design and application are welcome in this Special Issue.

### Guest Editor

Prof. Dr. Yunjin Jung

Laboratory of Biomedical Chemistry, College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea

### Deadline for manuscript submissions

closed (20 March 2019)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/19340](https://mdpi.com/si/19340)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).